SAB Biotherapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Samuel J. Reich
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2100 East 54th Street North Sioux Falls SD United States of America 57104
- IPO Date
- Feb 9, 2021
- CIK
- 0001833214
- Website
- sabbiotherapeutics.com
- Similar Companies
- Business
- SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical entity engaged in advancing immunotherapies that leverage fully human antibodies. The firm has harnessed sophisticated genetic engineering and antibody science to cultivate transchromosomic bovine herds capable of generating comprehensive human antibodies tailored to specific diseases, encompassing infectious conditions like severe influenza, as well as immune and autoimmune disorders such as type 1 diabetes. Utilizing its proprietary DiversitAb platform, the company efficiently produces high-potency, fully-human polyclonal antibodies without reliance on human donors, enabling rapid and scalable manufacturing. Its principal investigational asset, SAB-142, a fully-human anti-thymocyte immunoglobulin, is currently undergoing a registrational Phase 2b SAFEGUARD clinical trial for individuals with new-onset Stage 3 type 1 diabetes, with the first patient expected to be dosed by the end of 2025. Additionally, SAB-176, a multi-target biologic for treating or preventing severe influenza, has been granted both Breakthrough Therapy and Fast Track Designations by the FDA. The company also has programs targeting other areas, including earlier-stage candidates for antibiotic resistance and oncology, and previously completed a Phase 3 trial for SAB-185 against COVID-19. Established in 2014, the organization operates from its headquarters in Sioux Falls, South Dakota.
SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
SAB Biotherapeutics Q1 Earnings Call Highlights
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of “Moderate Buy” from Analysts
Head to Head Analysis: SAB Biotherapeutics (NASDAQ:SABS) versus Viking Therapeutics (NASDAQ:VKTX)
SAB BIO to Participate in Upcoming Investor Conferences
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management